Design of p53-derived peptides with cytotoxicity on breast cancer

Amino Acids

Volumn 46, Issue 8, 2014, Pages 2015-2024

  Fang, Yi ^a   Jin, Rongzhong ^b   Gao, Yinqi ^a   Gao, Jidong ^a   Wang, Jing ^a  

^a CANCER HOSPITAL   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cytotoxicity; MDM2; p53 protein; Peptide

Indexed keywords

ALANYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; GLUTAMYLALANYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLALANYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLALANYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLALANYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLALANYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLALANYLLEUCYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLALANYLPROLYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLALANYLGLUTAMIC ACID; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLALANINE; GLUTAMYLTHREONYLPHENYLALANYLSERYLASPARTYLLEUCYLTRYPTOPHYLLYSYLLEUCYLLEUCYLPROLYLGLUTAMIC ACID; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CANCER CELL LINE; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MDF 7 CELL LINE; MOLECULAR DYNAMICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION; WILD TYPE; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CHEMICAL STRUCTURE; FEMALE; GENETICS; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; POINT MUTATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904729102     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1750-y     Document Type: Article

References (40)

1. Amblard M, Fehrentz JA, Martinez J, Subra G (2006) Methods and protocols of modern solid phase peptide synthesis. Mol Biotech 33:239-254 (Pubitemid 44337228)
2. Anil B, Riedinger C, Endicott JA, Noble ME (2013) The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr D 69:1358-1366
3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242 (Pubitemid 30047768)
4. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229-239 (Pubitemid 39440251)
5. Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C (2012) Cannabinoids: a new hope for breast cancer therapy? Cancer Treat Rev 38:911-918
6. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688 (Pubitemid 43076180)
7. Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK (2013) Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA 110:3445-3454
8. Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol Cancer Res 2:20-28
9. Chi SW, Lee SH, Kim DH, Ahn MJ, Kim JS, Woo JY, Torizawa T, Kainosho M, Han KH (2005) Structural details on mdm2-p53 interaction. J Biol Chem 280:38795-38802 (Pubitemid 43853782)
10. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J (1992) p53 mutations in breast cancer. Cancer Res 52:5291-5298
11. Cui W, Wei Z, Chen Q, Cheng Y, Geng L, Zhang J, Chen J, Hou T, Ji M (2010) Structure-based design of peptides against G3BP with cytotoxicity on tumor cells. J Chem Inf Model 50:380-387
12. Darden T, York D, Pedersen L (1993) Particale mesh Ewald and N.log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092
13. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong GM, Zhang W (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 24:1999-2012
14. Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4:70-76 (Pubitemid 34248123)
15. Han K, Wu G, Lv F (2013) Development of QSAR-improved statistical potential for the structure-based analysis of protein-peptide binding affinities. Mol Inf 32:783-792
16. He P, Wu W, Wang HD, Yang K, Liao KL, Zhang W (2010) Toward quantitative characterization of the binding profile between the human amphiphysin-1 SH3 domain and its peptide ligands. Amino Acids 38:1209-1218
17. Hou T, Zhang W, Case DA, Wang W (2008) Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. J Mol Biol 376:1201-1214
18. Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810-8817 (Pubitemid 47437457)
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
20. Jin R, Ma Y, Qin L, Ni Z (2013) Structure-based prediction of domain-peptide binding affinity by dissecting residue interaction profile at complex interface: a case study on CAL PDZ domain. Protein Pept Lett 20:1018-1028
21. Jing T, Feng J, Li D, Liu J, He G (2013) Rational design of angiotensin-I-converting enzyme inhibitory peptides by integrating in silico modeling and an in vitro assay. ChemMedChem 8:1057-1066
22. Jochim AL, Arora PS (2009) Assessment of helical interfaces in protein-protein interactions. Mol BioSyst 5:924-926
23. Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897 (Pubitemid 32056774)
24. Li C, Pazgier M, Li C, Yuan W, Liu M, Wei G, Lu WY, Lu W (2010) Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 398:200-213
25. London N, Movshovitz-Attias D, Schueler-Furman O (2010) The structural basis of peptide-protein binding strategies. Structure 18:188-199
26. Mitchell JBO, Laskowski RA, Alex A, Thornton JM (1999) Potential of mean force describing protein-ligand interactions: I. Generating potential. J Comput Chem 20:1165-1176 (Pubitemid 129651749)
27. Petsalaki E, Russell RB (2008) Peptide-mediated interactions in biological systems: new discoveries and applications. Curr Opin Biotech 19:344-350
28. Popowicz GM, Domling A, Holak TA (2011) The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed 50:2680-2688
29. Ryckaert J, Ciccotti G, Berendsen HJC (1977) Numerical-integration of cartesian equations of motion of a system with constraints: moleculardynamics of n-alkanes. J Comput Phys 23:327-341
30. Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P (2012) PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 40:W288-W293
31. Tsui V, Case DA (2000) Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 56:275-291 (Pubitemid 34105875)
32. Vanhee P, Reumers J, Stricher F, Baeten L, Serrano L, Schymkowitz J, Rousseau F (2010) PepX: a structural database of nonredundant protein-peptide complexes. Nucleic Acids Res 38:D545-D551
33. Walker L, Perkins E, Kratz F, Raucher D (2012) Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm 436:825-832
34. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127-134
35. Wang Q, Canutescu AA, Dunbrack RL (2008) SCWRL and MolIDE: computer programs for side-chain conformation prediction and homology modeling. Nat Protoc 3:1832-1847
36. Wang S, Zhao Y, Bernard D, Aguilar A, Kumar S (2012) Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. Top Med Chem 8:57-80
37. Yang P, Du CW, Kwan M, Liang SX, Zhang GJ (2013) The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Sci Rep 3:2246
38. Zhou P, Tian F, Shang Z (2009) 2D depiction of nonbonding interactions for protein complexes. J Comput Chem 30:940-951
39. Zhou P, Tian F, Ren Y, Shang Z (2010) Systematic classification and analysis of themes in protein-DNA recognition. J Chem Inf Model 50:1476-1488
40. Zhou P, Wang C, Ren Y, Yang C, Tian F (2013) Computational peptidology: a new and promising approach to therapeutic peptide design. Curr Med Chem 20:1985-1996